The Biostatistics/Bioinformatics Core for The University of Texas MD Anderson Cancer Center SPORE in Brain Cancer is a comprehensive, multilateral resource for the design of basic science experiments and clinical trials, and appropriate statistical analysis ofthe resulting data. The Biostatistics and Bioinformatics Core incorporates sound experimental design principles that enhance interpretability of study results, . performs data analyses using appropriate methodology, and contributes to interpretation of results through written reports and frequent interaction with project investigators. Thus, from inception to reporting, translational experiments benefit from SPORE resources which are used to augment existing M.D. Anderson Cancer Center Biostatistics and Bioinformatics resources. The Biostatistics and Bioinformatics Core collaborates with all project investigators to facilitate the timely publication of all data collected under the Brain Cancer SPORE program. To serve all proposed SPORE Projects, as well as the Career Development and Developmental Research Programs, the Biostatistics/Bioinformatics Core has the following objectives: ? Provide biostatistics and bioinformatics expertise in the design and conduct of laboratory experiments and clinical trials arising from the research proposed in this application, ? Provide biostatistics and bioinformatics analysis and interpretation of all data collected under the SPORE Projects, Developmental Projects, and other Cores, and ? Collaborate and assist all project investigators with the publication of scientific results.
DO NOT EXCEED THE SPACE PROVIDED. Appropriate statistical analysis ofthe data resulting from translational research and the publication of the information is critical to the advancement and distribution of scientific information, through which the outcome of patients with malignant gliomas will be improved.
|Gressot, Loyola V; Doucette, Tiffany A; Yang, Yuhui et al. (2015) Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer 136:2047-54|
|Chen, James C; Alvarez, Mariano J; Talos, Flaminia et al. (2014) Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 159:402-14|
|Schrand, Brett; Berezhnoy, Alexey; Brenneman, Randall et al. (2014) Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res 2:867-77|
|Lang, Frederick F; Barker 2nd, Fred G (2014) A history of the AANS/CNS Section on Tumors Biennial Satellite Symposium. J Neurooncol 119:593-600|
|Olar, Adriana; Aldape, Kenneth D (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165-77|
|Singh, Mamata; Leasure, Justin M; Chronowski, Christopher et al. (2014) FANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene. Clin Cancer Res 20:3884-95|
|Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5|
|Conrad, Charles A; Fueyo, Juan; Gomez-Manzano, Candelaria (2014) Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again. Neuro Oncol 16:1025-6|
|Zhao, Jun; Wallace, Michael; Melancon, Marites P (2014) Cancer theranostics with gold nanoshells. Nanomedicine (Lond) 9:2041-57|
|Jiang, Hong; Clise-Dwyer, Karen; Ruisaard, Kathryn E et al. (2014) Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One 9:e97407|
Showing the most recent 10 out of 70 publications